Arvinas to Speak at Upcoming Investor Conferences

Arvinas, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker ARVN, has announced its participation in two forthcoming investor conferences. Arvinas is pioneering a novel class of drugs focused on targeted protein degradation.

The first conference, the BofA Securities 2024 Healthcare Conference, will take place on Tuesday, May 14, in Las Vegas at 3:00 p.m. PT. At this event, key representatives from Arvinas, including Chief Medical Officer Dr. Noah Berkowitz and Chief Business Officer Dr. Randy Teel, will engage in a fireside chat. For those unable to attend, a live audio webcast of the presentation will be accessible on the Company’s website, particularly in the Events and Presentations section.

The second event is the UBS Spring Biotech Conference, scheduled for Tuesday, May 21. During this conference, Dr. Noah Berkowitz and Dr. Randy Teel will also be available for one-on-one meetings with investors.

Arvinas is devoted to enhancing the lives of patients who are afflicted with severe and life-threatening illnesses. The company specializes in the discovery, development, and commercialization of therapies that target the degradation of disease-causing proteins. Central to their innovation is the proprietary PROTAC® Discovery Engine platform. This platform is designed to create proteolysis targeting chimeras, or PROTAC® protein degraders, which exploit the body’s natural protein disposal mechanisms to selectively and efficiently eliminate problematic proteins.

Apart from a strong preclinical pipeline targeting both validated and "undruggable" proteins, Arvinas boasts four clinical-stage investigational programs. These include vepdegestrant (ARV-471), which is aimed at treating patients with locally advanced or metastatic ER+/HER2- breast cancer. Also in clinical stages are ARV-766 and bavdegalutamide, both of which are being developed for men with metastatic castration-resistant prostate cancer. Additionally, ARV-102 is being investigated for its potential in treating patients suffering from neurodegenerative disorders.

Arvinas continues to make significant strides in the biotechnology realm with its innovative approach to protein degradation, offering new hope to patients with serious health conditions.